Floatz logo

Larotrectinib

Cervical Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

60 Active assets in the Cervical Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Advenchen Laboratories, LLC
Phase 3BB
Gardasil 9 Vaccine
Eunice Dube
Phase 4BB
Hepatitis B Virus Vaccine
Eunice Dube
Phase 4BB
Hycamtin
Advenchen Laboratories, LLC
Phase 3BB
Pembrolizumab
Mayo Clinic
Phase 2BB

View all 50 →

Same molecule, other indications

Larotrectinib is also rated in:

NTRK fusion positive cancerDormant
BB
Indicative ·
65 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
Locally Advanced Malignant Solid NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →